Genomma's Recovery Is Real — So Is the 165-Day Receipt

Genomma's Recovery Is Real — So Is the 165-Day Receipt

Genomma Lab's third quarter is a story about a company that believes it has found the floor — and is willing to pay for it in margin and in cash. The headline is that Mexico, after four ugly quarters, delivered a third consecutive sequential improvement in net sales, down just 2.4% versus minus 22.1% in Q4 2025. The undercard, though, is where the tension lives: the cash conversion cycle ballooned to 165 days from 129, and the man who has run the company for twelve years gave his farewell address while his CFO quietly admitted that the quarter's profit growth wasn't really operational.

The Turn Is Genuine — But It Was Bought

Start with what worked. Monitored sellout in Mexico returned to growth, and management walked through the monthly build: positive in July, stronger in August, +8.6% in September. At the leading retailer, the recovery ran hotter still, and the late-June innovation launch Suerox Mineral pushed the brand to a historic high value share of 12.6%, up six points in three months. “We held or grew market share across all business units and the innovation we launched in late June is already accelerating growth.” — Juan Marco Sparvieri, Chief Executive Officer · 2026-10-22

But management is explicit that this was purchased, not harvested. Gross margin fell 244 basis points to 61.4%, and EBITDA margin dropped 271 basis points to 21%, reflecting higher promotional investment plus the full absorption of Mexico's new tax on non-caloric sweetened beverages. The CEO framed it as a conscious trade: “I in particular, decided to err more on the risky side of investing more. But secure the market share recovery and the sellout.” — Juan Marco Sparvieri, Chief Executive Officer · 2026-10-22 That is the same posture he struck last quarter, when he told analysts “I do believe that we will see positive numbers in terms of sellout” — Juan Marco Sparvieri, Chief Executive Officer · 2026-07-23 — a forecast that has now been delivered on, which is worth noting in a market where such promises often slip.

The margin-recovery math is unchanged from July, which is itself telling. Management again points to a 23–24% consolidated EBITDA margin in 2027, with Mexico climbing back above 20% but perhaps not to its old 27%. “I am confident that we will see a gradual recuperation of our margin levels that were in the range of 23% to 24%.” — Juan Marco Sparvieri, Chief Executive Officer · 2026-07-23 Two consecutive calls, the same target — consistent, but also a reminder that this is a promise deferred by a full year.

165 Days: The Working-Capital Bill Comes Due

The quarter's most important disclosure isn't a growth number; it's the balance sheet. Receivables added 12 days, inventories 21, payables cost 3 — a 36-day jump that took the conversion cycle to 165 days. Management pre-empted the obvious analyst question with a dedicated slide, attributing 28 of the 36 days to two temporary effects: a 13-day Argentine noncash effect from inflation and peso devaluation, and a 15-day inventory build in Mexico ahead of the winter season.

There are 2 temporary effects that explain 28 of the 36 days which are a noncash inflationary accounting effect in Argentina, 13 days ... and a plant inventory build in Mexico of 15 days ahead of the winter season.

The commitment is to bring the cycle down to approximately 140 days by year-end — still above last year's level, as the CFO conceded. This is not new, exactly: receivables were the first question of the Q2 call, and the CEO then defended the same behavior as deliberate channel loading. “We are putting more product out there because we wanna have larger displays at the stores ... it is a choice we are making.” — Juan Marco Sparvieri, Chief Executive Officer · 2026-07-23 What has changed is that the choice now shows up as a 36-day swing in the metric investors watch most closely on this name.

The profit line deserves the same skepticism. Net margin expanded 168 basis points to 11.4% and net income rose 18.6% — but the CFO was refreshingly blunt that a foreign-exchange gain did the heavy lifting. “The FX gain is nonrecurring and without it, we have to acknowledge that this net income growth would have been lower.” — Antonio Zamora Galland, Chief Financial Officer · 2026-10-22 That kind of candor is rare and worth crediting.

The US Hole, the AI Pitch, and the Empty Chair

While Mexico healed, the United States deteriorated further. Net sales fell 30% on distribution gaps and continued Hispanic retail market weakness, with sellout down 8.8% in local currency. The quarter also ate a one-off hit from returned winter-season product after a milder-than-expected season — a US-specific problem management insists won't repeat. This is the structural soft spot the Mexican recovery is papering over, and it is the reason consolidated sales grew only 1.3% despite Latin America's 12.2%.

Then there is the transition. Marco Sparvieri confirmed this was his final earnings call as CEO, handing to founder-chairman Rodrigo Herrera on an interim basis January 1. His parting message folded in a new promotional hook: a December 3 Investor Day in New York to unveil a new operating model and an artificial intelligence platform — the closest this consumer staple gets to the financial discipline narrative leavened with an AI subplot. Investors should treat the AI framing as a marketing overlay until the December event delivers substance; nothing in these numbers depends on it.

The verdict: Genomma has genuinely turned the Mexican consumer franchise, and the Suerox innovation is a real, bankable win. But the quarter's quality is soft — profit helped by FX, cash consumed by inventory and Argentina accounting, margins sacrificed by design. The setup into Q4 and the CEO handover rests on three deliverables: winter inventory converting to cash, the cycle hitting 140 days, and the US stabilizing. Two of those are within management's control. The third is not.